High dose ascorbic acid treatment in COVID-19 patients raised some problems in clinical chemistry testing
Yıl: 2020 Cilt: 45 Sayı: 5 Sayfa Aralığı: 491 - 498 Metin Dili: İngilizce DOI: 10.1515/tjb-2020-0237 İndeks Tarihi: 18-11-2021
High dose ascorbic acid treatment in COVID-19 patients raised some problems in clinical chemistry testing
Öz: Objective: COVID-19 pandemia still continues to threatenthe whole world. High dose ascorbic acid (AA) infusion is achoice of treatment and its efficiency is still being investigated. AA interferes with many clinical chemistry tests.However, data about the interference of high concentrations of AA is not sufficient. In this study, we aimed toinvestigate the interference of AA at high concentrations oncommonly used chemistry assays.Materials and Methods: Serum samples at AA concentrations of 200, 150, 100, 75, 50, 25, 10, 5, 2 and 0 mg/dLwere prepared by using the stock solution of 15000 mg/dLAA. Each sample was analyzed by using the most common30 chemistry tests (Abbott Architect C8000, Illinois, USA)and a POCT glucometer (STANDARD GlucoNavii,Gyeonggi-do, Republic of Korea).Results: Creatinine, sodium and glucose (POCT) tests werefound to be positively interfered by increasing AA concentrations; while direct bilirubin, lipase, UIBC, triglyceride, total cholesterol, HDL/LDL cholesterol tests werenegatively interfered. Absolute interference (%) increasedas the AA concentration increased.Conclusion: This is the largest and first study to investigate the interference of high dose AA, which is used insevere COVID-19 patients nowadays. Manufacturers andclinicians should be aware of the possibility of aberrantresults due to high dose AA infusion. Clinicians should notforget to consult a laboratory specialist, since he is the onlyperson to monitor the reactions in all assays, and know thetechnical subjects like interferences, assay method specifications. This issue is very important for correct decisionmaking and interpretation of the data-mining studiesaccurately and efficiently
Anahtar Kelime: COVID-19 Hastalarında Kullanılan Yüksek Doz Askorbik Asit Tedavisi Klinik Kimya Testlerinde Bazı Sorunlara Neden Olmaktadır
Öz: Amaç: COVID-19 pandemisi hala tüm dünyayı tehdit etmeye devam etmektedir. Yüksek doz askorbik asit (AA) infüzyonu, tedavide bir seçenektir ve etkinliği hala ara ştırılmaktadır. AA birçok klinik biyokimya testini interfere eder. Fakat yüksek konsantrasyonlardaki AA interferansı hakkında veriler yetersizdir. Bu çalışmada, yüksek doz AA’nın yaygın kullanılan biyokimya testleri üzerindeki interferansını araştırmayı amaçladık. Gereç ve Yöntem: 15000 mg/dL AA stok solüsyonu kulla nılarak 200, 150, 100, 75, 50, 25, 10, 5, 2 and 0 mg/dL AA konsantrasyonlarına sahip serum örnekleri hazırlandı. En yaygın kullanılan 30 biyokimya testi (Abbott Architect C8000, Illinois, ABD) ve bir hasta başı test cihazı (HBTC) glukometre (STANDARD GlucoNavii, Gyeonggi-do, Kore Cumhuriyeti) kullanılarak, hazırlanan her serum örneğinin analizi yapıldı. Bulgular: Artan AA konsantrasyonlarıyla; kreatinin, sodyum ve glukoz (HBTC) testlerinde pozitif interferans olduğu; direkt bilirubin, lipaz, UIBC, trigliserit, total kolesterol, HDL/LDL kolesterol testlerinde ise negatif interferans olduğu bulundu. AA konsantrasyonu arttıkça interferans (%) büyüklüğü de artmaktaydı. Sonuç: Bu çalışma, son zamanlarda ciddi seyirli COVID-19 hastalarında kullanılan çok yüksek dozdaki AA’nın biyoki mya testleri üzerinde neden olduğu interferansı araştıran ilk ve en geniş çalışmadır. Üreticiler ve klinisyenler, yüksek doz AA infüzyonuna bağlı ortaya çıkabilecek anormal test sonuçlarının farkında olmalıdır. Klinisyenler böyle dur umlarda bir laboratuvar uzmanına danışmayı unutma malıdır. Çünkü laboratuvar uzmanı; tüm testlerdeki reaksiyonları takip edebilen, test metot özellikleri ve inter feranslar gibi teknik konuları bilen tek kişidir. Doğru karar verme ve veri madenciliği çalışmalarının doğru ve verimli olarak yorumlanması açısından bu konu çok önemlidir.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Sun P, Lu X, Xu C, Sun W, Pan B. Understanding of COVID-19 based on current evidence. J Med Virol 2020. https://doi.org/10.1002/ jmv.25804.
- 2. Fisher BJ, Seropian IM, Kraskauskas D, Thakkar JN, Voelkel NF, Fowler AA, et al. Ascorbic acid attenuates lipopolysaccharideinduced acute lung injury. Crit Care Med 2011; 39: 1454–60.
- 3. Carr AC. A new clinical trial to test high-dose vitamin C in patients with COVID-19. Crit Care 2020; 24: 133.
- 4. Clinical Trials. Vitamin C infusion for the treatment of severe 2019-nCoV infected pneumonia. Available from: https://www. clinicaltrials.gov/ct2/show/study/NCT04264533 [Accessed August 2020].
- 5. Clinical Trials. Use of ascorbic acid in patients with COVID 19. Available from: https://www.clinicaltrials.gov/ct2/show/ NCT04323514 [Accessed August 2020].
- 6. Burtis CA, Ashwood ER, Bruns DE, Tietz NW. Tietz textbook of clinical chemistry and molecular diagnostics. 5th ed. St. Louis, Mo: Saunders; 2013. xviii, 2,238 p.
- 7. Padayatty SJ, Sun AY, Chen Q, Espey MG, DriskoJ, Levine M. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PloS One 2010; 5: e11414.
- 8. Stephenson CM, Levin RD, Spector T, Lis CG. Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of highdose intravenous ascorbic acid in patients with advanced cancer. Canc Chemother Pharmacol 2013; 72: 139–46.
- 9. Duconge J, Miranda-Massari JR, Gonzalez MJ, Jackson JA, Warnock W, Riordan NH. Pharmacokinetics of vitamin C: insights into the oral and intravenous administration of ascorbate. Puert Rico Health Sci J 2008; 27: 7–19.
- 10. Martinello F, da Silva EL. Ascorbic acid interference in the measurement of serum biochemical parameters: in vivo and in vitro studies. Clin Biochem 2006; 39: 396–403.
- 11. Unic A, Nikolac Gabaj N, Miler M, Culej J, Lisac A, Horvat A, et al. Ascorbic acid-A black hole of urine chemistry screening. J Clin Lab Anal 2018; 32: e22390.
- 12. Karlsen A, Blomhoff R, Gundersen TE. Stability of whole blood and plasma ascorbic acid. Eur J Clin Nutr 2007; 61: 1233–6.
- 13. CLSI. Interference Testing in Clinical Chemistry; Approved Guideline—Second Edition. CLSI document EP07-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2005.
- 14. Westgard QC. Desirable biological variation database specifications. Available from: https://www.westgard.com/ biodatabase1.htm [Accessed August 2020].
- 15. Westgard QC. CLIA requirements for analytical quality. Available from: https://www.westgard.com/clia.htm [Accessed August 2020].
- 16. Data Innovations. Total allowable error table. Available from: https://datainnovations.com/allowable-total-error-table [Accessed August 2020].
- 17. CLSI. Point-of-Care Blood Glucose Testing in Acute and Chronic Care Facilities; Approved Guideline—Third Edition. CLSI document POCT12-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2013.
- 18. Fraser CG. Biological variation: from principles to practice. Washington, DC: AACC Press; 2001. xii, 151 p.
- 19. Meng QH, Irwin WC, Fesser J, Massey KL. Interference of ascorbic acid with chemical analytes. Ann Clin Biochem 2005; 42: 475–7.
- 20. Freemantle J, Freemantle MJ, Badrick T. Ascorbate interferences in common clinical assays performed on three analyzers. Clin Chem 1994; 40: 950–1.
- 21. Meng QH, Irwin WC, Visvanathan K. Vitamin C and aberrant electrolyte results. Clin Chem Lab Med 2005; 43: 454–6.
- 22. Martinello F, Luiz da Silva E. Mechanism of ascorbic acid interference in biochemical tests that use peroxide and peroxidase to generate chromophore. Clin Chim Acta 2006; 373: 108–16.
- 23. Lyon ME, Baskin LB, Braakman S, Presti S, Dubois J, Shirey T. Interference studies with two hospital-grade and two home-grade glucose meters. Diabetes Technol Therapeut 2009; 11: 641–7.
- 24. Yim J, Cho J, Ahn S, Lee SG, Kim JH. A practical way to overcome ascorbate interference in total cholesterol and triglyceride measurement by exploiting the autoxidation property of ascorbate. Clin Biochem 2017; 50: 350–1.
- 25. Stein EA, Myers GL. National cholesterol education Program recommendations for triglyceride measurement: executive summary. The national cholesterol education Program working group on lipoprotein measurement. Clin Chem 1995; 41: 1421–6.
- 26. Nah H, Yim J, Lee SG, Lim JB, Kim JH. Ascorbate oxidase minimizes interference by high-concentration ascorbic acid in total cholesterol assays. Ann Lab Med 2016; 36: 188–90.
- 27. Kayamori Y, Katayama Y, Urata T. Nonenzymatic elimination of ascorbic acid in clinical samples. Clin Biochem 2000; 33: 25–9.
- 28. Petrarulo M, Marangella M, Bianco O, Marchesini A, Linari F. Preventing ascorbate interference in ion-chromatographic determinations of urinary oxalate: four methods compared. Clin Chem 1990; 36: 1642–5.
- 29. Ceriello A. Hyperglycemia and the worse prognosis of COVID-19. Why a fast blood glucose control should be mandatory. Diabetes Res Clin Pract 2020:108186. https://doi.org/10.1016/j.diabres. 2020.108186.
- 30. Fan J, Wang H, Ye G, Cao X, Xu X, Tan W, et al. Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease. Metabolism 2019; 2020: 154243.
- 31. Hu X, Chen D, Wu L, He G, Ye W. Low Serum Cholesterol Level Among Patients with COVID-19 Infection in Wenzhou. China: SSRN; 2020. https://doi.org/10.2139/ssrn.com/ abstract=3544826 or https://doi.org/10.2139/ssrn.3544826.
- 32. Kim NY, Ha E, Moon JS, Lee YH, Choi EY. Acute hyperglycemic crises with coronavirus disease-19: case reports. Diabetes Metab J 2020; 44: 349–53.
- 33. Li Z, Liu G, Wang L, Liang Y, Zhou Q, Wu F, et al. From the insight of glucose metabolism disorder: oxygen therapy and blood glucose monitoring are crucial for quarantined COVID-19 patients. Ecotoxicol Environ Saf 2020; 197: 110614.
- 34. Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol 2020. https://doi.org/10.1002/jmv. 25770.
| APA | Yesildal F, İŞMAN F (2020). High dose ascorbic acid treatment in COVID-19 patients raised some problems in clinical chemistry testing. , 491 - 498. 10.1515/tjb-2020-0237 |
| Chicago | Yesildal Fatih,İŞMAN Ferruh Kemal High dose ascorbic acid treatment in COVID-19 patients raised some problems in clinical chemistry testing. (2020): 491 - 498. 10.1515/tjb-2020-0237 |
| MLA | Yesildal Fatih,İŞMAN Ferruh Kemal High dose ascorbic acid treatment in COVID-19 patients raised some problems in clinical chemistry testing. , 2020, ss.491 - 498. 10.1515/tjb-2020-0237 |
| AMA | Yesildal F,İŞMAN F High dose ascorbic acid treatment in COVID-19 patients raised some problems in clinical chemistry testing. . 2020; 491 - 498. 10.1515/tjb-2020-0237 |
| Vancouver | Yesildal F,İŞMAN F High dose ascorbic acid treatment in COVID-19 patients raised some problems in clinical chemistry testing. . 2020; 491 - 498. 10.1515/tjb-2020-0237 |
| IEEE | Yesildal F,İŞMAN F "High dose ascorbic acid treatment in COVID-19 patients raised some problems in clinical chemistry testing." , ss.491 - 498, 2020. 10.1515/tjb-2020-0237 |
| ISNAD | Yesildal, Fatih - İŞMAN, Ferruh Kemal. "High dose ascorbic acid treatment in COVID-19 patients raised some problems in clinical chemistry testing". (2020), 491-498. https://doi.org/10.1515/tjb-2020-0237 |
| APA | Yesildal F, İŞMAN F (2020). High dose ascorbic acid treatment in COVID-19 patients raised some problems in clinical chemistry testing. Türk Biyokimya Dergisi, 45(5), 491 - 498. 10.1515/tjb-2020-0237 |
| Chicago | Yesildal Fatih,İŞMAN Ferruh Kemal High dose ascorbic acid treatment in COVID-19 patients raised some problems in clinical chemistry testing. Türk Biyokimya Dergisi 45, no.5 (2020): 491 - 498. 10.1515/tjb-2020-0237 |
| MLA | Yesildal Fatih,İŞMAN Ferruh Kemal High dose ascorbic acid treatment in COVID-19 patients raised some problems in clinical chemistry testing. Türk Biyokimya Dergisi, vol.45, no.5, 2020, ss.491 - 498. 10.1515/tjb-2020-0237 |
| AMA | Yesildal F,İŞMAN F High dose ascorbic acid treatment in COVID-19 patients raised some problems in clinical chemistry testing. Türk Biyokimya Dergisi. 2020; 45(5): 491 - 498. 10.1515/tjb-2020-0237 |
| Vancouver | Yesildal F,İŞMAN F High dose ascorbic acid treatment in COVID-19 patients raised some problems in clinical chemistry testing. Türk Biyokimya Dergisi. 2020; 45(5): 491 - 498. 10.1515/tjb-2020-0237 |
| IEEE | Yesildal F,İŞMAN F "High dose ascorbic acid treatment in COVID-19 patients raised some problems in clinical chemistry testing." Türk Biyokimya Dergisi, 45, ss.491 - 498, 2020. 10.1515/tjb-2020-0237 |
| ISNAD | Yesildal, Fatih - İŞMAN, Ferruh Kemal. "High dose ascorbic acid treatment in COVID-19 patients raised some problems in clinical chemistry testing". Türk Biyokimya Dergisi 45/5 (2020), 491-498. https://doi.org/10.1515/tjb-2020-0237 |
